ReviewClinical and experimental immunology2017
Exosomes carrying immunoinhibitory proteins and their role in cancer.
Review in Clinical and experimental immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed.
- TCOF1 in extracellular vesicles predicts survival in patients with HCC treated with high-dose conformal radiotherapy.JHEP reports : innovation in hepatology · 2026Article
- From immune desert to hot tumor: the tripartite synergy of tumor microenvironment-exosomes-immunogenic cell death in pioneering solutions.Frontiers in immunology · 2026Review
- Prediction of Lymphovascular Invasion in Early-Stage Lung Adenocarcinoma Using Artificial Intelligence-Based Radiomics.Cancers · 2025Article
- Review
- Exosomes: a potential tool in the diagnosis, prognosis and treatment of patients with colorectal cancer.Future oncology (London, England) · 2025Review
- Natural and engineered extracellular vesicles in vascular diseases: a focus on therapeutic effects, challenges and prospective.European journal of medical research · 2025Review
- The Potential of Mesenchymal Stem Cell-Derived Exosomes to Treat Diabetes Mellitus.Biomimetics (Basel, Switzerland) · 2025Review
- Harnessing extracellular vesicle heterogeneity for diagnostic and therapeutic applications.Nature nanotechnology · 2025Review
- HIF-2α accumulation in human monocytes upon transfer of hypoxia-associated miRNAs via plasma-derived small extracellular vesicles from head and neck cancer patients.Frontiers in oncology · 2025Article
- Therapeutic and diagnostic implications of exosomes as natural nanoparticles: a new paradigm in brain cancer disease management.Frontiers in medicine · 2025Review
- The interplay between the tumor microenvironment and tumor-derived small extracellular vesicles in cancer development and therapeutic response.Cancer biology & therapy · 2024Review
- Article
- Mesenchymal Stem Cell-Derived Exosomes as Drug Delivery Vehicles in Disease Therapy.International journal of molecular sciences · 2024Review
- Tumor immune escape: extracellular vesicles roles and therapeutics application.Cell communication and signaling : CCS · 2024Review
- Mesenchymal stem cell transplantation plays a role in relieving cancer pain.Frontiers in pharmacology · 2024Review
- Communicator Extraordinaire: Extracellular Vesicles in the Tumor Microenvironment Are Essential Local and Long-Distance Mediators of Cancer Metastasis.Biomedicines · 2023Review
- Earlier Diagnosis of Pancreatic Cancer: Is It Possible?Cancers · 2023Review
- Extracellular vesicles in COVID-19 convalescence can regulate T cell metabolism and function.iScience · 2023Article
- Small EV in plasma of triple negative breast cancer patients induce intrinsic apoptosis in activated T cells.Communications biology · 2023Article
- Plasma‑derived CD16 exosomes and peripheral blood monocytes as correlating biomarkers in head and neck cancer.Oncology letters · 2023Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Recent emergence of exosomes as information carriers between cells has introduced us to a new previously unknown biological communication system. Multi-directional cross-talk mediated by exosomes carrying proteins, lipids and nucleic acids between normal cells, cells harbouring a pathogen or cancer and immune cells has been instrumental in determining outcomes of physiological as well as pathological conditions. Exosomes play a key role in the broad spectrum of human diseases. In cancer, tumour-derived exosomes carry multiple immunoinhibitory signals, disable anti-tumour immune effector cells and promote tumour escape from immune control. Exosomes delivering negative signals to immune cells in cancer, viral infections, autoimmune or other diseases may interfere with therapy and influence outcome. Exosomes can activate tissue cells to produce inhibitory factors and thus can suppress the host immune responses indirectly. Exosomes also promise to be non-invasive disease biomarkers with a dual capability to provide insights into immune dysfunction as well as disease progression and outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.